Madrigal Needs ResDifera Volume To Outrun Pricing And Cost Pressure As Shares Hit Lows

Madrigal Pharmaceuticals heads into its third-quarter report with an odd disconnect. The ResDifera launch has done nearly everything management promised, with active patients topping 50,000 in July and trailing sales near $1.3 billion. Yet the stock has slid 14.1% since the last report while the S&P 500 gained 3.3%. It now trades around $434, essentially at the bottom of its post-earnings range and below even the prior quarter's low. The market is not doubting demand so much as asking what that demand is worth after discounts, royalties and a much bigger sales force.

The Street expects revenue of about $400 million, up 39.3% from $287.3 million a year ago, with a loss of $1.09 per share versus $5.08 in the year-ago quarter. Sequentially, that is roughly a $36 million step up from the second quarter's $364.3 million, a smaller dollar gain than the $53 million jump the company just delivered. Management said last quarter it was comfortable with consensus quarterly growth, so the revenue bar looks reachable rather than heroic. Still, year-over-year growth has cooled from 127% in the first quarter to 71% in the second, and consensus implies another step down. That is mostly the math of lapping a fast launch, but it changes how the story reads.

The most useful number may be patient adds. Madrigal added roughly 6,000 to 7,000 active patients in each of the last several quarters, and management said the second quarter accelerated from the first. A similar or larger gain would back up the view that the new endocrinologist sales force and direct-to-consumer spending are widening the funnel. That matters because one-year persistency of about 60% to 70% means the company must keep finding new patients just to offset dropouts as the base grows. Slowing net adds would be the clearest sign that the launch curve is starting to bend.

Pricing is the other swing factor. Gross-to-net discounts moved from the 20% to 30% range in 2025 to the mid-to-high 30s for 2026, so each new prescription brings in less revenue. Any sign that discounts are drifting past that range would hurt confidence in revenue quality even if volume holds up. Margins need a cleaner look as well. Cost of sales jumped to $40 million last quarter on higher Roche royalties and a work-in-process inventory write-down, while SG&A reached $289.4 million. With the $25 million Arrowhead upfront payment behind it, the consensus loss assumes real operating leverage. A cost of sales line free of new write-downs, and SG&A growing more slowly than sales, would show that leverage is starting to appear. Cash stood at $838.9 million at midyear, and a smaller quarterly burn would ease funding worries as the pipeline grows.

The pipeline adds both promise and pressure. The oral GLP-1 MGL-2086 began Phase 1 dosing in June, and Phase 2 combination trials are planned for 2027. The F4C outcomes readout, which could roughly double the addressable opportunity, is still guided to 2027, but management has been vague about event accrual. Any firmer timeline would help. Hanging over the quarter is Inventiva's Phase 3 lanifibranor data, expected in the fourth quarter, which may explain some of the stock's weakness.

Sentiment has warmed sharply, from barely positive before the last report to clearly bullish now, even as the shares have fallen. That gap suggests many observers see the selloff as overdone. In the end, the report comes down to one question: can volume growth keep outpacing the drag from bigger discounts and rising costs? Strong patient adds and steadier margins would support the bullish case. Fading patient momentum would suggest the market's skepticism was justified.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.